Baloxavir for influenza: Enrichment obscured lack of effect in North-American adults. Author's reply

被引：1

作者：

de Haas, Esther C. ^{[1
]}

Luijendijk, Hendrika J. ^{[1
]}

机构：

[1] Univ Groningen, Univ Med Ctr Groningen, Dept Gen Practice & Elderly Care Med, POB 196, NL-9700 AD Groningen, Netherlands

来源：

关键词：

Clinical trial; Enrichment; Generalisability; Baloxavir; Influenza;

D O I：

10.1016/j.ejim.2019.12.021

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：102 / 102

页数：1

共 6 条

[1] de Haas Esther C., EUROPEAN J INTERNAL, V62, pe8
[2] Genentech USA Inc, 2018, XOFL BAL MARB LAB
[3] Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents
Hayden, Frederick G.
Sugaya, Norio
Hirotsu, Nobuo
Lee, Nelson
de Jong, Menno D.
Hurt, Aeron C.
Ishida, Tadashi
Sekino, Hisakuni
Yamada, Kota
Portsmouth, Simon
Kawaguchi, Keiko
Shishido, Takao
Arai, Masatsugu
Tsuchiya, Kenji
Uehara, Takeki
Watanabe, Akira
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (10) : 913 - 923
[4] Ison M. G., 2018, Open Forum Infect. Dis, V5, pS764, DOI [10.1093/ofid/ofy229.2190, DOI 10.1093/OFID/OFY229.2190]
[5] Japanese Pharmaceuticals and Medical Devices Agency, 2018, REV REP XOFL 10 MG 2
[6] Vald ~esL, 2003, EUR J INT MED, V14, P77